Median Technologies Gains FDA Clearance for AI Lung Cancer Screening Tool

Event summary

  • Median Technologies received FDA 510(k) clearance for eyonis® LCS, an AI-powered lung cancer screening tool, on February 9, 2026.
  • The software demonstrated 93.3% sensitivity, 92.4% specificity, and a 99.9% Negative Predictive Value in testing.
  • Approximately 14.5 million people in the U.S. are eligible for lung cancer screening, with an established reimbursement framework.
  • Median plans to commercialize eyonis® LCS through direct sales, partnerships, and integration into existing clinical environments.

The big picture

Median Technologies' FDA clearance for eyonis® LCS marks a significant milestone in AI-driven cancer screening, addressing a critical need in early lung cancer detection. With a worsening shortage of radiologists and rising screening volumes, the tool's ability to reduce inter-reader variability and improve diagnostic consistency positions it as a potential game-changer. The established reimbursement framework further accelerates adoption, creating immediate economic value for imaging providers.

What we're watching

Market Adoption
The pace at which healthcare systems integrate eyonis® LCS into existing workflows and the impact on screening volumes.
Regulatory Expansion
Whether Median can secure CE marking in Europe by Q2 2026, expanding access to the technology.
Competitive Dynamics
How eyonis® LCS will differentiate itself in a market with increasing AI-driven diagnostic tools.

Related topics

Technology